DOCSLIB.ORG

Treating Migraines in Patients with Psychiatric Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treating Migraines in Patients with Psychiatric Disorders Primary care update Current p SYCHIATRY How to control migraines in patients with psychiatric disorders Robert Smith, MD Lora A. Hasse, PhD Professor and director emeritus Research assistant professor of family medicine Department of family medicine Headache Research Unit Founder, Cincinnati Headache Center Department of family medicine University of Cincinnati University of Cincinnati Migraines often coexist with psychiatric disorders, including anxiety and major depression. Managing the headaches can improve psychiatric symptoms, too. any of the 28 million people who suffer from migraine headaches each year1 need psychiatric care M in addition to headache relief. Migraine headaches often coexist with depression,2 anxiety/panic disorders,2,3 bipo- lar disorder,4 and phobias,5 as well as with stroke6 and epilepsy.7 Table 1 A study of 995 young adults found that anxiety disorders, PSYCHIATRIC COMORBIDITIES IN phobias, major depression, panic disorder, and obsessive- PATIENTS WITH VS. WITHOUT MIGRAINES* compulsive disorder were two to five times more prevalent Migraineurs (%) Controls (%) among migraine sufferers than among a control group 2 (n = 128) (n = 879) (Table 1). Migraine sufferers know that at any time an attack Any anxiety 54 27 could hamper their ability to work, care for their families, Generalized anxiety disorder 10 2 or engage in social activities. A nationwide study of migraineurs found that attacks often impaired their rela- Phobia 40 21 tionships with family and friends.8 Major depression 35 10 Psychiatrists should screen patients for a history of Panic disorder 11 2 migraine or other headaches and carefully consider the Obsessive-compulsive disorder 92relationship between migraines and psychiatric disorders when prescribing treatment. In this article, we outline * Prevalence Source: Breslau N, Davis GC. Cephalalgia 1992;12(2):85-90. acute and preventive headache treatments and present two cases to help you treat these patients appropriately. VOL. 1, NO. 11 / NOVEMBER 2002 39 Migraine headaches Table 2 THREE TYPES OF PRIMARY HEADACHE: DIAGNOSTIC CRITERIA Headache type Age of onset Location Duration Frequency/ Severity Quality Features (years) timing Migraine 10 to 40 Hemicranial 4 to 72 hr Variable Moderate Throbbing, Nausea; to severe steady vomiting; ache photo/ phono/ osmophobia; neurologic deficits; aura Tension-type 20 to 50 Bilateral/ 30 min Variable Dull ache, Tight, Generally generalized to 7 days+ may wax band-like none and wane pressure Cluster 15 to 40 Unilateral, 15 to 180 1 to 8 times Excruciating Boring, Ipsilateral, periorbital or min per day or piercing conjunctival retro-orbital night injection, nasal congestion, rhinorrhea, miosis, facial seating Source: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(suppl 7):1-96. Headache definitions and diagnosis • New-onset headache late in life Primary or secondary. Under the International Headache • Headache with neurologic signs or symptoms such as Society’s (IHS) 1988 headache classification and diagnostic confusion, decreased level of consciousness, meningis- criteria,9 headaches are primary or secondary: mus, or papilledema • Primary headaches are benign recurrent headaches that • Headache following head trauma commonly present in practice. • Patient history of sickle cell disease, malignancy, or • Secondary headaches occur much less frequently and are HIV. caused by underlying pathology. Headache types. The three major types of primary headache The possibility of secondary headache should be ruled are migraine, tension-type, and cluster (Table 2). Tension-type out before a primary headache can be diagnosed. The follow- is the most common, is often mild, and is either self-treated ing headache features should cause concern: with over-the-counter medications or ignored. Migraine is the • Severe headache with abrupt onset most troublesome headache in everyday practice. Cluster is • Subacute or progressive headache over days or months the most severe and fortunately is rare. • Headache, nausea, vomiting, and fever not explained by Migraine with aura and migraine without aura are sepa- systemic illness rate diagnoses. IHS criteria for diagnosing migraines without 40 Current VOL. 1, NO. 11 / NOVEMBER 2002 p SYCHIATRY Current p SYCHIATRY aura are listed in Table 3. According to the IHS, Table 3 migraine with aura (or “classic migraine”) fulfills all DIAGNOSTIC REQUIREMENTS the criteria for migraine without aura, with fully FOR MIGRAINE WITHOUT AURA reversible neurologic symptoms indicating focal cere- bral cortical and/or brain stem dysfunction. Mandatory Auras. About 15% of migraineurs experience auras. 1. Secondary headache excluded Symptoms develop within 5 to 20 minutes, usually last 2. Duration 4 to 72 hours less than 1 hour, and fade before the headache’s onset. 3. At least 5 attacks Gradual onset and history of previous attacks helps to At least 2 of the following: distinguish aura from transient ischemic attacks. Auras 1. Location unilateral may manifest as visual, sensory, motor, or brain-stem 2. Pulsating/throbbing symptoms, or as combinations of these: 3. Moderate or severe headache (inhibits or prohibits • Visual auras are most common, presenting as routine activities) localized visual loss (scotoma), with flashing 4. Aggravated by walking stairs or similar activities lights (scintillation) at margins or jagged edges (fortification). During headache • Sensory auras present as facial or limb paresthesias. At least one of the following: • Motor auras manifest as weakness or lack of coordi- 1. Nausea and/or vomiting nation. 2. Photophobia and phonophobia • Brain stem auras manifest as vertigo or double vision. Additional features Migraine aura is considered part of the headache’s Migraine prodrome—A range of general, neurologic, and prodrome, which may occur days or hours before the mental changes may occur hours or days before the headache’s onset. The aura may bring about: headache’s onset • an altered mental state (e.g., depression, hyperactiv- General—Anorexia, food craving, diarrhea or constipation, ity, euphoria, difficulty concentrating, dysphasia) thirst, urination, fluid retention, cold feeling • neurologic symptoms (e.g., photophobia, phonopho- bia, hyperosmia, yawning) Mental—Depression, hyperactivity, euphoria, difficulty • general bodily discomforts (e.g., anorexia, food crav- concentrating, dysphasia ing, diarrhea, thirst, urination, fluid retention, cold Neurologic—Photophobia, phonophobia, hyperosmia, feeling). yawning Despite their sometimes severe effects, migraines SOURCE: Classification and diagnostic criteria for headache disorders, cranial neuralgias 10 often remain undiagnosed. Migraine should be suspect- and facial pain. Headache Classification Committee of the International Headache Society. ed in patients with recurrent moderate to severe disabling Cephalalgia 1988;8(suppl 7):1-96. headaches (Box).11-15 Case 1: “Bad, sick headaches” times lasted 2 to 3 days. Bed rest helped but this was not Ms. A, 23, a single parent with a 2-year-old child, has had always possible. The headache was throbbing and usually trouble staying employed because of repeated illnesses. She one-sided. She had no aura, and ibuprofen gave partial relief. made 17 visits to her primary care physician within 26 She noted that her mother gets similar headaches. months. While her main complaint was headache, she also Ms. A was diagnosed with migraine without aura, and complained of other aches and pains, a lack of energy, and she was treated with sumatriptan, 100 mg (1 or 2 doses, as insomnia. Numerous examinations revealed no physical needed). Her headaches responded well to this treatment, but abnormalities. the frequency of attacks remained unchanged. She requested She reported having “bad, sick headaches” that some- a change in her medicine. continued VOL. 1, NO. 11 / NOVEMBER 2002 41 Migraine headaches Box Treating the psychiatric comorbidity WHAT CAUSES MIGRAINE HEADACHES? Behavioral therapy is used as an adjunct to pharmacologic headache treatment. This he underlying mechanisms of migraine headaches are not approach is usually considered after a poor or Tcompletely understood. adverse response to treatment, or when phar- Vascular causes. A recently described neurovascular macologic treatment is contraindicated (e.g., mechanism11 suggests that perivascular neurogenic inflammation during pregnancy). involving meningeal vessels causes migraine. The triptan drugs have Relaxation training, biofeedback, and been found to reverse this process and relieve the headache.12 cognitive-behavioral stress management are Positron emission tomography has demonstrated increased blood the most commonly used forms of behavioral flow during acute migraine in midline brain stem structures. This therapy. Thirty-five to 55% improvement in suggests the presence of a central migraine generator in that migraine has been reported following such 16 location.13 treatments. Heredity. A rare form of migraine, familial hemiplegic migraine, Cognitive-behavioral intervention has 17 is associated with a genetic abnormality on chromosome 19.14 been shown to be effective in depression 18 Nitric oxide. Nitroglycerine-induced migraine headache, caused and anxiety disorders. When either psychi- by the release of nitric oxide in cerebral vessels, can be reversed by atric problem is comorbid with migraine, nitrous oxide synthase inhibitors,
Load more

Recommended publications
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • The Migraine Attack As a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory
    ISSN 0017-8748 Headache doi: 10.1111/head.13214 VC 2017 American Headache Society Published by Wiley Periodicals, Inc. Views and Perspectives The Migraine Attack as a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory Jonathan M. Borkum, PhD Background.—Previous research has suggested that migraineurs show higher levels of oxidative stress (lipid peroxides) between migraine attacks and that migraine triggers may further increase brain oxidative stress. Oxidative stress is trans- duced into a neural signal by the TRPA1 ion channel on meningeal pain receptors, eliciting neurogenic inflammation, a key event in migraine. Thus, migraines may be a response to brain oxidative stress. Results.—In this article, a number of migraine components are considered: cortical spreading depression, platelet acti- vation, plasma protein extravasation, endothelial nitric oxide synthesis, and the release of serotonin, substance P, calcitonin gene-related peptide, and brain-derived neurotrophic factor. Evidence is presented from in vitro research and animal and human studies of ischemia suggesting that each component has neuroprotective functions, decreasing oxidant production, upregulating antioxidant enzymes, stimulating neurogenesis, preventing apoptosis, facilitating mitochondrial biogenesis, and/or releasing growth factors in the brain. Feedback loops between these components are described. Limitations and challenges to the model are discussed. Conclusions.—The theory is presented that migraines are an integrated
    [Show full text]
  • PMA-Sio2: Heteropolyacid Catalysis for Michael Addition-Convenient Route to Substituted-3-Indoles
    Available online at www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2017, 9(13):112-117 CODEN (USA): PCHHAX (http://www.derpharmachemica.com/archive.html) PMA-SiO2: Heteropolyacid Catalysis for Michael Addition-Convenient Route to Substituted-3-Indoles Vijay Kumar Pasala* Deapartment of Chemistry, Osmania University, Hyderabad-500007, Telangana, India ABSTRACT Synthesis of 3-substituted indoles in a hassel-free, ecofriendly manner by treating indoles with α, β-unsaturated carbonyl or nitro compounds under acidic conditions to give good to excellent yields with shorter reaction durations are described. The catalyst is recyclable for three to four times without great loss in the activity. Keywords: Phosphomolybdic Acid (PMA), Substituted indoles, α, β-unsaturated carbonyl compounds, α, β-unsaturated nitro compounds, Michael addition INTRODUCTION Heterocyclic chemistry is one of the quintessential branches of organic synthesis beaconing towards new scaffolds with medicinal values, new methodologies to the existing active principles etc. One among such skeletons is indole. It is perhaps the most common heterocycles in chemistry and its derivatives are obtained from coal pitch, variety of plants or by the bacterial decay of tryptophan in the intestine [1]. Indole derivatives serve as signaling chemicals in plants and animals, as nucleus building blocks (serotonin [2] (A) a crucial neurotransmitter in the central nervous system [3]), as antibacterial [4], antiviral [5], protein kinase inhibitors [6], anticancer agents [7], entheogens (psilocybin (B) causes perceptional changes), hormones (melatonin (C) regulates sleep and wakefulness), antidepressants (roxindole (D), bufotenin (E)), sumatriptan (F) for the treatment of migraine and ondansetron (G) for the suppression of nausea and vastly found in natural products such as alkaloids (Corynanthe, Iboga, and Aspidosperma alkaloids) [8-10], indigoids etc., which originate, either fully or partly, from bio-oxidation of indoles [11].
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Loss of Taste and Smell After Brain Injury
    Loss of taste and smell after brain injury Introduction Following a brain injury many people report that their senses of taste and/or smell have been affected. This may be as a consequence of injury to the nasal passages, damage to the nerves in the nose and mouth, or to areas of the brain itself. Loss or changes to smell and taste are particularly common after severe brain injury or stroke and, if the effects are due to damage to the brain itself, recovery is rare. The effects are also often reported after minor head injuries and recovery in these cases is more common. If recovery does occur, it is usually within a few months of the injury and recovery after more than two years is rare. Sadly, there are no treatments available for loss of taste and smell, so this factsheet is designed to provide practical suggestions on how you can compensate. It provides information on health, safety and hygiene issues, suggestions to help you to maintain a healthy, balanced diet, information on psychological effects and some other issues to consider. How are taste and smell affected by brain injury? The two senses can both be affected in a number of different ways and some definitions of the terms for the different conditions are provided below: Disorders of smell Anosmia Total loss of sense of smell Hyposmia Partial loss of sense of smell Hyperosmia Enhanced sensitivity to odours Phantosmia/Parosmia ‘False’ smells – Perceiving smells that aren’t there Dysosmia Distortion in odour perception Disorders of taste Dysgeusia Distortion or decrease in the sense of taste Ageusia Total loss of sense of taste Dysgensia Persistent abnormal taste Parageusia Perceiving a bad taste in the mouth 1 The two senses are connected and much of the sensation of taste is due to smell, so if the sense of smell is lost then the ability to detect flavour will be greatly affected.
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • European Patent Office of Opposition to That Patent, in Accordance with the Implementing Regulations
    (19) TZZ _T (11) EP 2 666 772 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 409/04 (2006.01) C07D 209/16 (2006.01) 01.03.2017 Bulletin 2017/09 C07D 209/18 (2006.01) C07D 209/38 (2006.01) (21) Application number: 13173141.6 (22) Date of filing: 12.12.2003 (54) Synthesis of amines and intermediates for the synthesis thereof Synthese von Aminen und Zwischenverbindungen für die Synthese davon Synthèse d’amines et intermédiaires pour leur synthèse (84) Designated Contracting States: • DEMERSON C A ET AL: "ETODOLIC ACID AND AT BE BG CH CY CZ DE DK EE ES FI FR GB GR RELATED COMPOUNDS CHEMISTRY AND HU IE IT LI LU MC NL PT RO SE SI SK TR ANTIINFLAMMATORY ACTIONS OF SOME POTENT DI-AND TRISUBSTITUTED (30) Priority: 20.12.2002 EP 02406128 1,3,4,9-TETRAHYDROPYRANO not 3,4-B 3/4 INDOLE-I-ACETIC ACIDS", JOURNAL OF (43) Date of publication of application: MEDICINALCHEMISTRY, AMERICAN CHEMICAL 27.11.2013 Bulletin 2013/48 SOCIETY, vol. 19, no. 3, 1 March 1976 (1976-03-01), pages391-395, XP000940626, ISSN: (62) Document number(s) of the earlier application(s) in 0022-2623, DOI: 10.1021/JM00225A010 accordance with Art. 76 EPC: • HARUYASU ET ALL: "Possible metabolic 03799560.2 / 1 572 647 Intermediatesfrom IAA to beta-acid in Rice Bran", AGR. BIOL. CHEM., vol. 40, no. 12, 1976, pages (73) Proprietor: BASF SE 2465-2470, XP002714693, 67056 Ludwigshafen am Rhein (DE) • SOLL R M ET AL: "Multigram preparation of 1,8-diethyl-7-hydroxy-1,3,4,9-tetrahydropy (72) Inventors: rano[3,4-b]indole-1-acetic acid, a phenolic • Berens, Ulrich metabolite of the analgesic and antiinflammatory 79589 Binzen (DE) agent etodolac", THE JOURNAL OF ORGANIC • Dosenbach, Oliver CHEMISTRY, AMERICAN CHEMICAL SOCIETY 79415 Bad Bellingen (DE) [NOT]ETC.
    [Show full text]
  • Patient Information Leaflet
    Package Leaflet: Information for the user Sumatriptan 50 mg film-coated tablets Sumatriptan 100 mg film-coated tablets sumatriptan Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Sumatriptan tablet is and what it is used for 2. What you need to know before you use Sumatriptan tablet 3. How to use Sumatriptan tablet 4. Possible side effects 5. How to store Sumatriptan tablet 6. Contents of the pack and other information 1. What Sumatriptan tablet is and what it is used for Sumatriptan belongs to a group of medicines called serotonin receptor (5-HT1) agonists. Migraine headaches are thought to result from the dilatation of blood vessels. Sumatriptan constricts these blood vessels, thus relieving the migraine headache. Sumatriptan tablet is used to treat migraine attacks with or without aura (aura is a premonition usually connected with flashes of light, serrated images, stars or waves). 2. What you need to know before you use Sumatriptan tablet Do not use Sumatriptan tablet: - if you are allergic to sumatriptan or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Medication Guide 2012
    DeKalb County D.U.I. Court Supervised Treatment Program MEDICATION GUIDE Medication Guide 2012 DeKalb County State Court Decatur, Georgia xxi ********** WELCOME TO THE DEKALB COUNTY D.U.I. COURT SUPERVISED TREATMENT PROGRAM. This 2012 Medication Guide was developed as a collaborative effort by Becky Pirouz, Pharm.D., Director of Pharmacy, Peachford Hospital, and by Lois Michalove, Treatment Coordinator for the DeKalb County D.U.I. Court Supervised Treatment Program, both of whom have extensive experience in addiction recovery and treatment. ********** The following information is intended to assist you in making decisions about medications. This may include those medications that you are prescribed and/or your selection of over-the-counter (OTC) products. Unintended exposure may compromise your treatment program. This is not an exhaustive list, but contains some of the medications that are most commonly used. If in doubt, always consult the Treatment Coordinator. Please inform your physician, dentist, pharmacist and other health care professionals that you are in a recovery program. WE ARE A ZERO-TOLERANCE PROGRAM! DO NOT COMPROMISE YOUR RECOVERY BY MAKING HIGH-RISK CHOICES! xxii - Section 1 – Drugs To Avoid The following drugs must not be used at any time. They are well known to be abused and even small amounts may result in relapse and are contraindicated in your treatment program. However, extenuating circumstances may occur which necessitates the short- term limited use of some of the drugs on this list in consultation with your physician, the Judge and the Treatment Coordinator. This decision should be made prior to your ingestion of any of the Drugs to Avoid.
    [Show full text]
  • Let's Talk About . . . Migraine and Dizziness
    LET’S TALK ABOUT . MIGRAINE AND DIZZINESS Migraine is almost as common as high blood Key points pressure in the Canadian population. It is more • A migraine is a severe headache. common than asthma or diabetes. An estimated 300,000 Canadians suffer needlessly because they • Of over 300 types of migraine, dizziness is have either been misdiagnosed or not diagnosed a symptom of two: migraine with brainstem with chronic migraine. aura and vestibular migraine. • See a doctor who specialized in headaches for accurate diagnosis. What are the symptoms of migraine with dizziness? • Lifestyle changes may help prevent or lessen the occurrence of migraine. Common symptoms include: • Medication may help prevent migraine. • Visual aura – you may see flashes of light or have blind spots in your vision. • Localized pain behind or near the eye on one Note: Concussion also causes migraine-type side of your head. dizziness – concussion sufferers can substitute the • Light, sound (hyperacusis) and odor sensitivity word “concussion” for “migraine” in the information (hyperosmia). You may have some sensitivity below. daily and increased sensitivity when you have migraine. • Visual vestibular mismatch (the brain’s What is migraine? hypersensitivity to motion) is common in Migraine is a neurovascular headache, meaning it migraine-type brains both episodically and can be triggered by annoyance or disturbance to chronically. Sometimes it will occur without the nerves or blood vessels in the brain. All headache and you may feel “off” for an hour or migraines are caused by the same type of two. neurotransmitter dysregulation and respond to the • Vertigo (spinning sensation) – it may start same treatments.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Olfactory Dysfunction
    Olfactory Dysfunction: By Steven Sobol, MD, MSc; Saul Frenkiel, MD, FRCSC; and Debbie Mouadeb he sense of smell plays an important role in protecting Tman from environmental dangers, such as fire, natural gas leaks and spoiled food. Physiologically, the chemical senses aid in normal digestion by triggering gastrointestinal secretions.1 Smell influences the palatability of food. Defects in the sense of smell are associated with alterations in perceptions of flavor, leading to anorexia and weight loss. Psychologically, smell is powerful in establishing strong positive and negative memories, and affects socialization and interpersonal relationships. Smell dysfunctions often mean considerable disability and a lower quality of life. Loss or decreased olfactory function affects approximately one per cent of Americans under the age of 60 and more than half the population over that age.2 Aside from having a substantial impact on an individual’s quality of life, olfactory dysfunction may signal an underlying disease. Smell disorders have been largely overlooked by the medical community because of a lack of knowledge and understanding of the sense of smell and its disease states, as well its diagnosis and management. Patients with olfactory disorders need to be clinically assessed, and the etiology and anatomical location of their disorder should be sought out. The Canadian Journal of Diagnosis / August 2002 55 Olfactory Dysfunction Summary What are the causes of olfactory dysfunction? 1.Conductive olfactory loss is any process that causes sufficient obstruction in the nose preventing odorant molecules from reaching the olfactory epithelium. 2.Sensorineural olfactory loss is any process that directly affects and impairs either the olfactory epithelium or the central olfactory pathways.
    [Show full text]